rsv f

Ziresovir (RO-0529) is a respiratory syncytial virus fusion protein (RSV F) inhibitor that inhibits RSV activity and can be used in the study of syncytial virus sensing.

Anti-Human respiratory syncytial virus (RSV) Fusion Glycoprotein RSV-F Antibody (1B191) is a Rabbit IgG monoclonal antibody targeting RSV Human respiratory syncytial virus (RSV) Fusion Glycoprotein RSV-F.

Anti-RSV-F Antibody (AM22) is an antibody. Its expression system is CHO cells, the clone number is AM22, and the isotype control is IgG1, Kappa.

Anti-RSV-F HMPV-F Antibody (MPE8) is an antibody. Its expression system is CHO cells, the clone number is MPE8, and the isotype control is IgG1, Lambda.

Anti-RSV-F Antibody (4D7) is an antibody. Its expression system is CHO cells, the clone number is 4D7, and the isotype control is IgG1, Kappa.

BMS-433771, a novel inhibitor of respiratory syncytial virus (RSV), binds the RSV F glycoprotein and inhibits membrane fusion.

JNJ-2408068 is an inhibitor of respiratory syncytial virus (RSV). JNJ-2408068 exhibited potent antiviral activity with EC50 of 2.1 nM. A similar inhibitory effect was observed in a RSV-mediated cell fusion assay (EC50= 0.9 nM). JNJ-2408068 interferes with

RSV-IN-5 is a potent dual inhibitor of wild-type and mutant respiratory syncytial virus (RSV) fusion proteins.RSV-IN-5 was able to act on wild-type A2 F protein and D486N mutant F protein with EC50 values of 2.0 nM and 8.1 nM, respectively, and exhibited potent anti-RSV effects.

Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).

Felvizumab (SB 209763), a humanized IgG1κ monoclonal antibody, targets specific neutralizing epitopes on the F glycoprotein of Respiratory Syncytial Virus (RSV) [1] [2].

Gontivimab (ALX-0171) is a trivalent nanobody targeting the hRSV fusion (F) protein with anti-RSV antiviral properties for the study of respiratory syncytial virus infections.

Sisunatovir hydrochloride (RV521 HCl) is an orally available inhibitor of the RSV-F protein that has exhibited potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses in vitro (IC50 = 1.4 nM for RSV-A, IC50 = 1.0 nM for RSV-B).

RSM01 is a fully human IgG1 monoclonal antibody that targets a site in the pre-F region of RSV with a YTE half-life prolongation mutation.